Genetics in Diagnosing and Managing Inflammatory Bowel Disease

Gastroenterology Clinics of North America

Volumn 41, Issue 2, 2012, Pages 513-522

  McCauley, Jacob L ^a   Abreu, Maria T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Gene chips; Genomic medicine; Next generation sequencing; Pharmacogenomics

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; FUNGUS ANTIBODY; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 23; LACTOFERRIN; MERCAPTOPURINE; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; THIOPURINE METHYLTRANSFERASE;

AP 1 GENE; ATG16L1 GENE; AUTOIMMUNE DISEASE; CARD15 GENE; CARD9 GENE; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DLG5 GENE; DRUG EFFICACY; DRUG METABOLISM; ENTERITIS; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; HEREDITY; HERITABILITY; HUMAN; I KAPPA B ALPHA GENE; IL23 GENE; INCIDENCE; MDR1 GENE; MIF GENE; NOD2 GENE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PREVALENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TNF GENE; TPMT GENE; ULCERATIVE COLITIS;

BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84859649829     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.01.002     Document Type: Review

References (38)

1. Menon R., Riera A., Ahmad A. A global perspective on gastrointestinal diseases. Gastroenterol Clin North Am 2011, 2:427-439. ix.
2. Molodecky N.A., Soon I.S., Rabi D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142(1):46-54.
3. Hou J.K., El-Serag H., Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol 2009, 8:2100-2109.
4. Johnston R.D., Logan R.F. What is the peak age for onset of IBD?. Inflamm Bowel Dis 2008, 14(Suppl 2):S4-S5.
5. Ishihara S., Aziz M.M., Yuki T., et al. Inflammatory bowel disease: review from the aspect of genetics. J Gastroenterol 2009, 11:1097-1108.
6. Peeters M., Cortot A., Vermeire S., et al. Familial and sporadic inflammatory bowel disease: different entities?. Inflamm Bowel Dis 2000, 4:314-320.
7. Brant S.R., Nguyen G.C. Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis?. Inflamm Bowel Dis 2008, S2-S3.
8. Orholm M., Munkholm P., Langholz E., et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 2:84-88.
9. Brant S.R. Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 2011, 1:1-5.
10. Glocker E.O., Kotlarz D., Boztug K., et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009, 21:2033-2045.
11. Glocker E.O., Frede N., Perro M., et al. Infant colitis-it's in the genes. Lancet 2010, 9748:1272.
12. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 6837:599-603.
13. Barrett J.C., Hansoul S., Nicolae D.L., et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 8:955-962.
14. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 7152:427-434.
15. Franke A., McGovern D.P., Barrett J.C., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010, 12:1118-1125.
16. Anderson C.A., Boucher G., Lee C.W., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011, 3:246-252.
17. Lees C.W., Barrett J.C., Parkes M., et al. New IBD genetics: common pathways with other diseases. Gut 2011, 60(12):1739-1753.
18. Cho J.H., Brant S.R. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 2011, 6:1704-1712.
19. Thompson A.I., Lees C.W. Genetics of ulcerative colitis. Inflamm Bowel Dis 2011, 3:831-848.
20. Rivas M.A., Beaudoin M., Gardet A., et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet 2011, 11:1066-1073.
21. Gregersen P.K., Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009, 27:363-391.
22. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat Rev Genet 2009, 1:43-55.
23. Cortes A., Brown M.A. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011, 1:101.
24. Feero W.G., Guttmacher A.E., Collins F.S. Genomic medicine-an updated primer. N Engl J Med 2010, 21:2001-2011.
25. Bloss C.S., Schork N.J., Topol E.J. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011, 6:524-534.
26. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980, 5:651-662.
27. Cuffari C. The genetics of inflammatory bowel disease: diagnostic and therapeutic implications. World J Pediatr 2010, 3:203-209.
28. Vermeire S., Van Assche G., Rutgeerts P. Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 2010, 21:2609-2615.
29. Booth R.A., Ansari M.T., Loit E., et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011, 12:814-823. W-295-8.
30. Weersma R.K., Stokkers P.C., van Bodegraven A.A., et al. Molecular prediction of disease risk and severity in a large Dutch Crohn's disease cohort. Gut 2009, 3:388-395.
31. Henckaerts L., Van Steen K., Verstreken I., et al. Genetic risk profiling and prediction of disease course in Crohn's disease patients. Clin Gastroenterol Hepatol 2009, 9:972-980.e2.
32. Vermeire S., van Assche G., Rutgeerts P. Review article: altering the natural history of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther 2007, 1:3-12.
33. Arijs I., Li K., Toedter G., et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009, 12:1612-1619.
34. Lee J.C., Lyons P.A., McKinney E.F., et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011, 10:4170-4179.
35. Lewis J.D. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011, 6:1817-1826. e2.
36. Tamboli C.P., Doman D.B., Patel A. Current and future role of biomarkers in Crohn's disease risk assessment and treatment. Clin Exp Gastroenterol 2011, 4:127-140.
37. Lichtenstein G.R., Targan S.R., Dubinsky M.C., et al. Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior. Inflamm Bowel Dis 2011, 12:2488-2496.
38. van Limbergen J., Philpott D., Griffiths A.M. Genetic profiling in inflammatory bowel disease: from association to bedside. Gastroenterology 2011, 5:1566-1571. e1.